Autonomic Technologies
Stage
Acquired | AcquiredTotal Raised
$98.62MAbout Autonomic Technologies
Autonomic Technologies (ATI) is a medical device company headquartered in the San Francisco Bay Area with offices in Germany and Switzerland, focused on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. The company's initial product, the Pulsante microstimulator, is CE marked in Europe for the treatment of cluster headache. The device is also under an IDE study in the US for the treatment of chronic cluster headache.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Autonomic Technologies Patents
Autonomic Technologies has filed 41 patents.
The 3 most popular patent topics include:
- Neurological disorders
- Bones of the head and neck
- Neurophysiology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/21/2018 | 6/20/2023 | Neurophysiology, Analgesics, Neurological disorders, Acute pain, Sensory systems | Grant |
Application Date | 12/21/2018 |
|---|---|
Grant Date | 6/20/2023 |
Title | |
Related Topics | Neurophysiology, Analgesics, Neurological disorders, Acute pain, Sensory systems |
Status | Grant |
Latest Autonomic Technologies News
Mar 21, 2023
News provided by Share this article Share this article KELOWNA, BC, March 21, 2023 /PRNewswire/ - AUTONOMIC TECHNOLOGIES INC. is pleased to announce the launch of its fellowship program, aimed at helping founders and their teams impacted by the Silicon Valley Bank failure, improve brain performance, productivity, and manage stress levels during times of uncertainty and high-demand. The fellowship program is designed specifically to support founders and their teams manage stress and optimize overall brain performance during this turbulent time. By providing access to cutting-edge brain performance software, research, resources, and performance coaching, the program aims to equip founders with the skills they need to get their teams productivity and focus back on track. "At Autonomic, we understand the unique challenges that founders face when trying to build and scale a successful business including the impact this all can have on brain function and performance." "Under the current circumstances with Silicon Valley Bank (SVB) founders need to come together and support one another in the ways we best know how. That's why we've created this fellowship program." The fellowship program will include a range of resources and services, including: Full access to Autonomic software for employees One-on-one coaching sessions for founders with Jamie Wood Access to proprietary research and operational frameworks Team workshops/training sessions on topics such as leadership optimization, cognitive optimization, and resilience Networking opportunities with other founders and industry experts Ongoing support and guidance from a dedicated program team "The bank run might be over, but getting your team's productivity and focus back is not. Doing so requires increased brain performance. Dealing with the challenges of getting back on track shouldn't be faced alone." said Jamie Wood. We encourage all founders who are passionate about improving their brain performance and reducing stress to apply for our fellowship program and become part of this supportive community. Together, we can help each other thrive and achieve our goals. The fellowship program is open to founders from all industries and backgrounds who have been impacted by the (SVB) failure. Applications are now open, and the first cohort will begin in April 2023. For more information about the fellowship program, including eligibility requirements and application details, visit Autonomic's website at www.getautonomic.com/fellowship SOURCE Autonomic Technologies Inc.
Autonomic Technologies Frequently Asked Questions (FAQ)
Where is Autonomic Technologies's headquarters?
Autonomic Technologies's headquarters is located at 3698 Haven Avenue, Redwood City.
What is Autonomic Technologies's latest funding round?
Autonomic Technologies's latest funding round is Acquired.
How much did Autonomic Technologies raise?
Autonomic Technologies raised a total of $98.62M.
Who are the investors of Autonomic Technologies?
Investors of Autonomic Technologies include Realeve, HBM Healthcare Investments, InterWest Partners, Kleiner Perkins Caufield & Byers, Aberdare Ventures and 7 more.
Who are Autonomic Technologies's competitors?
Competitors of Autonomic Technologies include Relievant Medsystems, MedShape, Cianna Medical, Inspire Medical Systems, TearScience and 12 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Autonomic Technologies to Competitors
Linguaflex is a medical device company with a patent pending technology to treat obstructive sleep apnea. LinguaFlex's LTR is implanted and designed to be comfortable, therefore addressing the lack of compliance as an issue in the successful treatment of OSA.
Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the ßAir. The company's flagship product is called the ßAir Bio-artificial Pancreas. It is in development as a treatment and potential cure for type 1 diabetes (T1D). ßAir was first designed to address the main problems of the otherwise successful procedures in which islets of Langerhans (i.e. pancreatic endocrine cells) are transplanted in diabetic patients, such as the need for life-long immunosuppressive pharmacological treatment and limited functionality of the transplanted islets over time due to an insufficient oxygen supply. The company's second pipeline product is the ßAir Bio-artificial Adrenal for the treatment of adrenocortical insufficiency and other stress-related disorders. This product is currently at the pre-clinical stage of development.
AllTranz aims to provide relief from chronic pain to patients outside the hospital setting.
Stealth mode medical device company developing devices for drug delivery. Monterey Devices submitted a patent on device for buffering anesthetics.
Salutaris Medical Devices (SalutarisMD) is a clinical-stage medical device company developing an investigational ophthalmic treatment for Wet Age-related Macular Degeneration (Wet AMD). SalutarisMD is developing a minimally invasive procedure that can be performed in an outpatient or physician office setting in approximately 15 minutes.
BioWave is a neuromodulation pain therapy company whose major goal is to help physicians, physical therapists and athletic trainers manage their patients' or athletes pain and reduce or eliminate the use of opiates, NSAIDs and their associated side effects. Biowave devices deliver a therapeutic electrical signal into deep tissue in the body blocking the transmission of pain.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
